Alcohol use associated alterations in the circulating metabolite profile in the general population and in individuals with major depressive disorder

Olli Kärkkäinen\textsuperscript{a, *}, Tommi Tolmunen\textsuperscript{b,c}, Petri Kivimäki\textsuperscript{b,d}, Karoliina Kurkinen\textsuperscript{b}, Toni Alisisto\textsuperscript{b}, Pekka Mäntyselkä\textsuperscript{c,f}, Minna Valkonen-Korhonen\textsuperscript{b,g}, Heli Koivumaa-Honkanen\textsuperscript{b}, Kirsi Honkalampi\textsuperscript{h}, Anu Ruusunen\textsuperscript{a,g,i}, Vidya Velagapudi\textsuperscript{j}, Soili M. Lehto\textsuperscript{k,l,m}

\textsuperscript{a} School of Pharmacy, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland

\textsuperscript{b} Institute of Clinical Medicine/Psychiatry, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland

\textsuperscript{c} Department of Adolescent Psychiatry, Kuopio University Hospital, P.O. Box 100. 70029 KYS, Finland

\textsuperscript{d} City of Helsinki, Vuosaari Outpatient Psychiatry Clinic. Postal address: P.O. Box 6250, FI-00099 City of Helsinki, Helsinki, Finland

\textsuperscript{e} Clinical Research and Trials Centre, Kuopio University Hospital, P.O. Box 100. 70029 KYS, Finland

\textsuperscript{f} Institute of Public Health and Clinical Nutrition, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland

\textsuperscript{g} Department of Psychiatry, Kuopio University Hospital, Kuopio, Finland

\textsuperscript{h} School of Educational Sciences and Psychology, University of Eastern Finland, P.O. Box 111, 80101 Joensuu. Finland

\textsuperscript{i} Deakin University, IMPACT - the Institute for Mental and Physical Health and Clinical Translation, Food & Mood Centre, IMPACT Strategic Research Centre, School of Medicine, P.O. Box 281, Geelong, VIC 3220, Australia

\textsuperscript{j} Metabolomics Unit, Institute for Molecular Medicine Finland FIMM, P.O. Box 20, FI-00014 University of Helsinki, Finland

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Institute of Clinical Medicine, University of Oslo, Oslo, Norway

R&D Department, Division of Mental Health Services, Akershus University Hospital, Lørenskog, Norway

Psychiatry, University of Helsinki and Helsinki University Hospital, P.O. Box 20, FI-00014 Helsinki, Finland

* Correspondence: olli.karkkainen@uef.fi, School of Pharmacy, University of Eastern Finland, P.O. Box 1627, 70211, Kuopio, Finland

Running title: Alcohol, metabolites, and depression

Keywords: Depression; Alcoholism; Metabolomics; Hippurate; 5-hydroxyindoleacetic acid
ABSTRACT

Our aim was to evaluate whether alcohol use is associated with changes in the circulating metabolite profile similar to those present in persons with depression. If so, these findings could partially explain the link between alcohol use and depression. We applied a targeted liquid chromatography mass spectrometry method to evaluate correlates between concentrations of 86 circulating metabolites and self-reported alcohol use in a cohort of the non-depressed general population (GP) (n = 247) and a cohort of individuals with major depressive disorder (MDD) (n = 99). Alcohol use was associated with alterations in circulating concentrations of metabolites in both cohorts. Our main finding was that self-reported alcohol use was negatively correlated with serum concentrations of hippuric acid in the GP cohort. In the GP cohort, consumption of six or more doses per week was associated with low hippuric acid concentrations, similar to those observed in the MDD cohort, but in these individuals it was regardless of their level of alcohol use. Reduced serum concentrations of hippuric acid suggest that already moderate alcohol use is associated with depression-like changes in the serum levels of metabolites associated with gut microbiota and liver function; this may be one possible molecular level link between alcohol use and depression.
Introduction

Heavy alcohol use and lifetime occurrence of alcohol use disorder have been associated with an increased incidence of a major depressive disorder (MDD) (Grant et al., 2015; McHugh & Weiss, 2019; Odlaug et al., 2016). It has been estimated that around one in six of persons with MDD is suffering from a current alcohol use disorder, and that around every third person with MDD has had a lifetime occurrence of alcohol use disorder (DeVido & Weiss, 2012; Sullivan et al., 2005; Swendsen et al., 1998). However, the relationship between moderate alcohol use and the incidence of MDD remains controversial: some studies show possible small increase in the incidence of MDD (Odlaug et al., 2016), whereas others have not been able to detect any associations (García-Esquinas et al., 2018) or even found evidence for a reduced incidence of MDD (Bellos et al., 2016). Light alcohol use has not been associated with an increased risk of MDD, and light drinkers are commonly used as controls in these studies (Bellos et al., 2016; García-Esquinas et al., 2018; Grant et al., 2015; Odlaug et al., 2016).

One possible mediating effect between alcohol use and MDD are changes in the activity of many metabolic processes. Heavy alcohol use has been associated with an altered metabolome (for a review see Voutilainen and Kärkkäinen, 2019). For example, increased levels of glutamate, citrate, alanine, phenylalanine, tyrosine, glucose, docosahexaenoate, 2-piperidone and phosphatidylcholine diacyls, and decreased levels of glutamine, serotonin, asparagine, hydroxysphingomyelins, gamma-aminobutyric acid (GABA) and phosphatidylcholine acyl-alkyls have been associated with heavy alcohol use (Heikkinen et al., 2019; Jaremek et al., 2013; Kärkkäinen, Farokhnia, et al., 2021; Kärkkäinen, Kokla, et al., 2021; Lehikoinen et al., 2018; Würtz et al., 2016). In a prospective study with an over 30
years’ follow-up, changes in the circulating metabolome, e.g., decreased levels of serotonin and asparagine, preceded the diagnosis of diseases related to alcohol use (Kärkkäinen et al., 2020). Similarly, also MDD has been associated with alterations in circulating levels of metabolites – some of which have also been linked to alcohol use (e.g., glutamate, phenylalanine, citrate and serotonin; for a review see Gadad et al., 2018). This evidence, in addition to the observed overlap in the incidences of MDD and alcohol use, imply that there may well be some shared underlying pathology related to the disturbances in metabolic processes.

We have now investigated whether alcohol use would be associated with similar changes in the circulating metabolite profiles irrespective of the presence of depression by measuring the associations between serum metabolite concentrations and self-reported alcohol use in two cohorts: a non-depressed general population (GP) cohort and a cohort of individuals with MDD.
Material and methods

Study cohorts

Two cohorts were used: 1) a general population cohort of non-depressed individuals (GP cohort), and 2) patients with major depressive disorder (MDD cohort) (Ali-Sisto et al., 2016; Kraav et al., 2019). Both cohorts represented the same population, as Kuopio University Hospital from where the MDD cohort was recruited serves the municipality area of Lapinlahti from where the GP cohort was recruited. The Ethics Committee of Hospital District of Northern Savo approved both studies. Participants provided written informed consent before entering the studies.

The non-depressed GP cohort was from a population-based follow-up study consisting of 480 individuals living in the municipality area of Lapinlahti, Finland in 2005. The sample described here was collected as a part of a 5-year follow-up of the study in 2010 (n = 326) but only participants with alcohol use data (n = 289). Further exclusion criteria were a) Beck Depression Inventory (BDI) score of ≥ 10 at the time of the study or 5 years earlier (Beck, 1961), or b) use of medication for depression. After exclusions, a total of 247 subjects were included in the study (Table 1).

The MDD cohort consisted of 99 outpatients with MDD who were recruited from the Department of Psychiatry of Kuopio University Hospital, Finland. The diagnosis of MDD was confirmed with the structured clinical interview for DSM-IV (SCID) (DSM-IV; American Psychiatric Association, 1994). The exclusion criteria were a) bipolar disorder, b) psychotic disorders, c) a symptomatology of mental illness due to alcohol or substance abuse-related diagnosis, d) epilepsy, and e) current somatic conditions preventing participation in
the study visits. Most of the participants in the MDD cohort were being administered some form of psychotropic medication: 81 had been prescribed with an antidepressant medication and 48 with an antipsychotic drug with some indication other than a psychotic disease (the medication use has been described in detail in Ali-Sisto, et al. 2016).

Alcohol use

The participants in both cohorts completed self-report questionnaires from which the weekly alcohol use was extracted. Response alternatives were: < 1 drink/week, 1-2 drink(s)/week, 3-5 drinks/week, 6-9 drinks/week, 10-14 drinks/week, 15-21 drinks/week, 22-28 drinks/week, or > 28 drinks/week. One standard drink in Finland is defined as a drink containing 12 grams of ethanol. Values higher than 21 drinks per week were considered heavy use, between 6 and 21 drinks per week moderate use, and below 6 drinks per week light drinking.

Background data, depressive symptoms and psychiatric medications

Background data was collected from the questionnaires completed by the participants. Depressive symptoms were assessed with the Beck Depression Inventory (Beck, 1961) in both cohorts. The use of prescription and over-the-counter medications was also recorded with a questionnaire and confirmed from the prescription documents that the participants provided. The following variables were also collected from both cohorts: age (in years), gender (female/male), regular smoking (yes/no), cohabitation status (married or living with a partner vs. living alone), and education level (higher education yes/no). Use of vegetables and use of fruits (< 1 time/week, 1-5 times/week, > 5 times/week, according to Savolainen et al. 2014), and body mass index (BMI) were only available in the GP cohort.
Metabolite profiling analysis

Venous blood samples were obtained via venipuncture by trained laboratory personnel and centrifuged to separate the serum. Before venipuncture, the participants were instructed to fast for 12 hours. Serum samples were stored frozen at -80 °C until analyzed. The samples were analyzed in the metabolomics unit of the Institute of Molecular Medicine Finland (FIMM) in Helsinki, Finland. Metabolite profiling analysis of the samples was performed using liquid chromatography-mass spectrometry. Briefly, 10 µL of labeled internal standard mixture was added to the 100 µL of samples, and the samples were allowed to equilibrate with the internal standards. A total of 400 µL of extraction solvent (1% formic acid in acetonitrile) was added and the collected supernatant was dispensed into an OstroTM 96-well plate (Waters Corporation, Milford, USA) and then filtered by applying a vacuum at a delta pressure of 300–400 mbar for 2.5 minutes on a Hamilton robot's vacuum station. After this, 5 µL of filtered sample extract was injected into an Acquity UPLC system coupled to a Xevo® TQ-S triple quadrupole mass spectrometer (Waters Corporation, Milford, MA, USA), which was operated in both positive and negative polarities with a polarity switching time of 20 msec for metabolite separation and quantification. The Multiple Reaction Monitoring (MRM) acquisition mode was selected for the quantification of the metabolites. MassLynx 4.1 software was used for data acquisition, data handling, and instrument control. The data were processed using TargetLynx software.

Statistics

In the comparison of the background characteristics of the cohorts, we used Mann-Whitney U test for continuous and $\chi^2$ test for binomial variables.
For the metabolite profiling data, only metabolites that were above the quantification limits in at least 50% of subjects in at least one cohort were included in the study. Metabolite concentrations below the quantification limit were excluded from the analysis, with the exception of cotinine, where concentrations below the quantification limit were considered to be zero.

In the statistical analysis of the metabolite data, the self-reported weekly alcohol drinking levels were coded numerically (1 = < 1 drink/week, 2 = 1–2 drink(s)/week, 3 = 3-5 drinks/week, 4 = 6–9 drinks/week, 5 = 10–14 drinks/week, 6 = 15–21 drinks/week, 7 = 22–28 drinks/week, and 8 = > 28 drinks/week) to allow us to conduct a regression analysis. We analyzed the two cohorts separately for changes in the metabolite concentrations associated with alcohol use. This was done to focus the analysis on alcohol use related changes, not to changes associated with MDD, which have been reported earlier (Ali-Sisto et al. 2016). We used linear regression to investigate correlations between self-reported weekly alcohol drinking and serum metabolite concentrations. To account for multiple testing, we undertook a principal component analysis and used the number of principal components needed to explain 95% of variance in the datasets to adjust the α-level using Bonferroni’s method to 0.001 (46 and 41 principal components were needed to explain 95% of variance in the GP and MDD cohorts, respectively). Metabolites with p-values between 0.05 and 0.001 were considered as trends.

For metabolites with a p-value below 0.05 in the initial analysis, we conducted a post-hoc analysis using linear regression with possible confounders previously associated with alcohol
use and/or metabolite levels (age, sex, use of vegetables, use of fruits, smoking, BMI, education level, and cohabitation status) as covariates. We used JASP (version 0.14), SIMCA (version 17, Umetrics), and Prism (GraphPad Software Inc., version 7) for statistical analyses, multivariate analysis, and figure preparation, respectively.
Results

The characteristics of the study participants in both cohorts are presented in Table 1. The GP cohort was older than the MDD cohort. With respect to the selection criteria, as would be expected, the MDD cohort had higher BDI scores when compared to the non-depressed GP cohort. Subjects in the MDD cohort were living alone and smoked regularly more often when compared to the GP cohort.

The correlations found between self-reported alcohol use and serum metabolite concentrations with p-value below 0.05 in at least one cohort are shown in Figure 1. However, at the multiple testing adjusted α level of 0.001, the only significant correlations were observed between self-reported alcohol use and serum concentrations of hippuric acid and chenodeoxycholic acid in the GP cohort, and xanthosine in the MDD cohort (Figure 1). Correlations with p-values between 0.05 and 0.001 should be considered as trends that need to be validated in larger cohorts. The correlations between self-reported alcohol use and all 86 measured metabolites are shown in the Supplementary Table 1.

A post-hoc analysis was conducted using linear regression with potential confounders. In the GP cohort, most of the correlations between self-reported alcohol use and metabolite levels remained significant after taking into account possible confounders (hippuric acid $\beta = -0.19$, $p = 0.0037$; chenodeoxycholic acid $\beta = 0.19$, $p = 0.0049$; cytidine $\beta = 0.22$, $p = 0.0011$; 5-HIAA $\beta = -0.16$, $p = 0.0183$; taurocholic acid $\beta = 0.22$, $p = 0.0012$; glutamine $\beta = -0.20$, $p = 0.0040$; and serine $\beta = -0.16$, $p = 0.0218$). There were two exceptions; glycine ($\beta = -0.12$, $p = 0.0785$) and cotinine ($\beta = 0.03$, $p = 0.5005$). Instead of alcohol use, sex correlated more with the glycine concentration ($\beta = -0.15$ and $p = 0.0382$) and smoking status more with cotinine.
concentrations ($\beta = 0.74$, $p < 0.0001$). In the MDD cohort, all metabolites with a $p$-value below 0.05 in the initial analysis also had a $p$-value below 0.05 in the linear regression models when lifestyle factors were included as covariates (xanthosine $\beta = -0.38$, $p = 0.0002$; GABA $\beta = 0.25$, $p = 0.0186$; cytidine $\beta = 0.21$, $p = 0.0388$; carnosine $\beta = -0.21$, $p = 0.0348$; and 2-aminoisobutyric acid $\beta = 0.22$, $p = 0.0336$).
Discussion

Our main finding was that in the GP cohort, at least moderately increased alcohol use was associated with lower serum concentrations of hippuric acid. The hippuric acid concentrations in those individuals who reported six or more alcohol doses per week were similar to the concentrations observed in the MDD cohort regardless of their level of alcohol use (Figure 1). These results are in line with previous reports, where decreased levels of hippuric acid have been associated with alcohol use, depression, anxiety disorders, and stress (J. Chen et al., 2018; Kärkkäinen et al., 2020; Phua et al., 2015; P. Zheng, Wang, et al., 2013; P. Zheng, Chen, et al., 2013). Although rather little is known to explain how hippuric acid might influence behavior, previous studies have found that low hippuric acid levels may impair neuronal development in fetal mouse brain (Ahmed et al., 2022; Vuong et al., 2020).

Moreover, in humans, low serum hippuric acid concentrations have been associated with mild cognitive impairment, whereas high levels of hippuric acid have been linked with beneficial effects on cognitive performance (Rutledge et al., 2021; Yilmaz et al., 2020).

In the GP cohort, similar trends were also seen in the association between self-reported alcohol use and concentrations of 5-HIAA and histidine. Interestingly, the composition of gut microbiota may influence the serum levels of the following three compounds, i.e., hippuric acid (Behr et al., 2017; Fujisaka et al., 2018; Lees et al., 2013; Pessa-Morikawa et al., 2022; Vuong et al., 2020; Williams et al., 2010), 5-HIAA (Lukić et al., 2019), and histidine (H. Chen et al., 2019; Kawase et al., 2017). Moreover, both alcohol use and MDD have been associated with an altered composition and changes in the function of the gut microbiota (Kelly et al., 2016; Leclercq et al., 2014; Llopis et al., 2016; Winter et al., 2018; P. Zheng et
Therefore, alterations in the gut microbiota could explain the correlations between serum levels of these metabolites, alcohol use and depression.

However, in the case of hippuric acid, the gut microbiota first makes benzoic acid from phenolic compounds in the diet, and then the liver forms hippuric acid by combining benzoic acid with glycine (Lees et al., 2013). The declines in serum hippuric acid concentrations could therefore also be a reflection of disturbed liver function since decreased hippuric acid production has been associated with alcohol use and impaired liver function (van Sumere et al., 1969). Furthermore, the intake of vegetables or fruits, the main sources of phenolic compounds in the diet, did not significantly correlate with serum hippuric acid concentrations in the present study. Therefore, differences in the intakes of food items with phenolic compounds are not a likely explanation for the changes we observed in serum levels of hippuric acid. More research is needed to clarify the role of hippuric acid in alcohol use and depression.

Moreover, we also observed a positive correlation between self-reported alcohol consumption and serum concentrations of two bile acids, chenodeoxycholic acid and taurocholic acid. These correlations could be associated with altered bile acid synthesis or metabolism, which can also be linked with the gut microbiota (Bajaj, 2019). Increases in serum levels of bile acids have been associated with the organ damage induced by alcohol consumption (Bajaj, 2019; Milstein et al., 1976; Trinchet et al., 1994). Interestingly, there was no correlation between self-reported alcohol use and chenodeoxycholic acid levels in the MDD cohort, which could be associated with altered cholesterol metabolism in MDD since cholesterol is a starting precursor for bile acid formation (Kraav et al., 2019; Lehto et al., 2010). Moreover,
in the MDD cohort, we observed a negative correlation between xanthosine and self-reported alcohol use, which was not observed in the GP cohort. This difference is likely linked to the previously reported dysregulation of purine metabolism in the same cohort (Ali-Sisto et al., 2016).

Furthermore, there were several metabolites, which were positively (cytidine, taurocholic acid) or negatively (glycine, serine and glutamine) correlated with self-reported alcohol use in both the GP and MDD cohorts with similar standardized β coefficients (Figure 1). However, due to the smaller sample size, these correlations were not statistically significant in the MDD cohort. These alterations are in line with results from previous studies investigating changes associated with alcohol use in the human circulating metabolome (Kärrkäinen et al., 2020; Lehikoinen et al., 2018; Voutilainen & Kärkkäinen, 2019; Würtz et al., 2016).

Limitations of the study include the relatively small number of subjects in the MDD cohort. Based on the present results, moderate alcohol use seems to be associated with small-to-medium effect size changes in the serum metabolite profile and therefore future studies should examine larger cohorts. We estimated that a sample size of 315 would be needed to observe small-to-medium effect size ($f^2 > 0.1$) correlations between alcohol use and metabolite concentrations with the corrected α level used in the present study (0.0001) with 0.95 statistical power. Furthermore, future studies should also use other biomarkers such as phosphatidylethanol, to assess recent alcohol use instead of relying solely on self-reporting (Y. Zheng et al., 2011).
The present results show that already moderate alcohol use is associated with depression-like changes in the serum levels of a metabolite, hippuric acid, which has been linked with both the gut microbiota and liver function. This indicates that changes in the metabolites associated with the gut microbiota and liver function could be one of the molecular level links between alcohol use and depression, although further research will be needed to verify this hypothesis.
Funding source

This work was supported by The Finnish Foundation for Alcohol Studies (OK), and the Finnish Medical Foundation (SML).

Declaration of competing interest

OK is a co-founder of Afekta Technologies Ltd., company providing metabolomics analysis services (not used in the present study). All other authors have no conflicts of interest to declare.

Acknowledgements

The authors wish to thank Dr. Jorma Savolainen for his significant contribution in the collection of the Lapinlahti Study sample, and Dr. Ewen MacDonald for proofreading.

Data availability statement

The data that support the findings of this study are available on request from the corresponding author, OK. The data are not publicly available due to their containing information that could compromise the privacy of research participants. The study plan approved by the ethical committee and the participant consent terms preclude public sharing of these sensitive data, even in anonymized form.
References


contributes to individual susceptibility to alcoholic liver disease. 

Gut, 65(5), 830–839.

https://doi.org/10.1136/gutjnl-2015-310585


Alcohol Research: Current Reviews, 40(1), arcr.v40.1.01. https://doi.org/10.35946/arcr.v40.1.01


Alcohol and Alcoholism, 51(2), 201–209. https://doi.org/10.1093/alcalc/agv088


BMC Microbiology, 22(1), 46. https://doi.org/10.1186/s12866-022-02457-6


Journal of Proteome Research, 14(11), 4734–4742.

https://doi.org/10.1021/acs.jproteome.5b00603


Food & Function, 12(1), 107–118. https://doi.org/10.1039/d0fo02125c


Zheng, Y., Beck, O., & Helander, A. (2011). Method development for routine liquid chromatography–mass spectrometry measurement of the alcohol biomarker phosphatidylethanol (PEth) in...

https://doi.org/10.1016/j.cca.2011.04.022
Table 1: Background characteristics of the study cohorts.

<table>
<thead>
<tr>
<th>Variable</th>
<th>GP (n = 247)</th>
<th>MDD (n=99)</th>
<th>test value</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Age (years, mean ±SD)</strong></td>
<td>54.6 (±9.5)</td>
<td>39.4 (±11.9)</td>
<td>4213&lt;sup&gt;b&lt;/sup&gt;</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Gender (% females)</td>
<td>118 (48 %)</td>
<td>56 (56%)</td>
<td>2&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.1393</td>
</tr>
<tr>
<td>Living with a partner (n, %)</td>
<td>206 (83%)</td>
<td>52 (53%)</td>
<td>37&lt;sup&gt;a&lt;/sup&gt;</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>BDI score (mean ±SD)</td>
<td>3 (±2)</td>
<td>28 (±12)</td>
<td>22733&lt;sup&gt;b&lt;/sup&gt;</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Self-reported alcohol use (n, %)</td>
<td></td>
<td></td>
<td>13&lt;sup&gt;a&lt;/sup&gt;</td>
<td>0.0742</td>
</tr>
<tr>
<td><strong>Light alcohol use</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;1 doses/week</td>
<td>75 (30%)</td>
<td>34 (34%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-2 doses/week</td>
<td>59 (24%)</td>
<td>26 (26%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>3-5 doses/week</td>
<td>58 (23%)</td>
<td>17 (17%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Moderate alcohol use</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>6-9 doses/week</td>
<td>26 (10%)</td>
<td>15 (15%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>10-14 doses/week</td>
<td>23 (9%)</td>
<td>2 (2%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>15-21 doses/week</td>
<td>5 (2%)</td>
<td>2 (2%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Heavy alcohol use</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>22-28 doses/week</td>
<td>1 (0.4%)</td>
<td>2 (2%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;28 doses/week</td>
<td>0 (0%)</td>
<td>1 (2%)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Smoking (n, %)</td>
<td>48 (19%)</td>
<td>33 (33%)</td>
<td>18&lt;sup&gt;a&lt;/sup&gt;</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Antidepressant use (n, %)</td>
<td>0 (0%)</td>
<td>84 (85%)</td>
<td>277&lt;sup&gt;a&lt;/sup&gt;</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>BMI (mean ±SD)</td>
<td>28 (±5)</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Use of vegetables (n, %)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;5 times/week</td>
<td>81 (32%)</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-5 times/week</td>
<td>85 (34%)</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;1 times/week</td>
<td>86 (34%)</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Use of fruits (n, %)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>&gt;5 times/week</td>
<td>95 (38%)</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1-5 times/week</td>
<td>88 (35%)</td>
<td>-</td>
<td></td>
<td></td>
</tr>
<tr>
<td>&lt;1 times/week</td>
<td>69 (27%)</td>
<td>-</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Legend: GP, general population cohort; MDD, cohort of patients with a major depressive disorder; BDI, Beck Depression Inventory; BMI, body mass index; SD, standard deviation; significant difference between the study cohorts as evaluated by: <sup>a</sup> = χ2 test, or <sup>b</sup> = Mann-Whitney U test.
Figure 1: Metabolites associated with self-reported alcohol use. Standardized β coefficients are shown (with 95% confidence intervals as dashed lines) for linear regression models between measured metabolites and self-reported alcohol use with negative (A) or positive (B) correlations. After correction for multiple testing, only correlations between self-reported alcohol use and chenodeoxycholic acid, hippuric acid and xanthosine can be viewed as significant (p-values below multiple testing adjusted α of 0.001). Other correlations should be considered as trends. Legend: GP, general population cohort; MDD, major depressive disorder cohort; β, standardized β coefficient from linear regression model; p, p-value from linear regression model; *, p-value < 0.001 (Bonferroni adjusted α level).